Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Individual Patient Expanded Access Investigation New Drug (IND) Application for Administration of Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Sponsors

Lead Sponsor: Celltex Therapeutics Corporation

Source Celltex Therapeutics Corporation
Brief Summary

This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.

Overall Status Available
Study Type Expanded Access
Condition
Intervention

Intervention Type: Drug

Intervention Name: Adipose-Derived Mesenchymal Stem Cells

Eligibility

Criteria:

Inclusion Criteria: - The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability. - All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined - Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy. Exclusion Criteria: - Current diagnosis of malignancy - Renal/liver dysfunction: Exceed two times as normal subject - Pregnant or nursing - Received other trial drugs within 30 days after participation of this study - Experienced major surgery or trauma in the last 14 days

Gender:

All

Minimum Age:

N/A

Maximum Age:

N/A

Overall Official
Last Name Role Affiliation
Richard L Neel, M.D. Principal Investigator Little Alsace Urgent Care Center
Overall Contact

Last Name: Jane Young, M.D., Ph.D

Phone: 713-817-8987

Email: [email protected]

Verification Date

2020-12-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News